Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 1c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $44.39 million versus the consensus estimate of $43.11 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2024 revenue of $170-200 million, versus the consensus of $184.1 million. And year-end cash, cash equivalents, and short-term investments of $55M-$75M

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance
• Constellation Brands (STZ) Tops Q1 EPS by 18c
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations